Biological therapy and nail psoriasis

Dermatologic Therapy

Volumn 20, Issue 1, 2007, Pages 60-67

  Lawry, Monica ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

Biological therapy; Nail psoriasis; Psoriatic arthritis; Treatment

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIHISTAMINIC AGENT; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; EFALIZUMAB; ETANERCEPT; FLUOROURACIL; INFLIXIMAB; NIMESULIDE; PLACEBO; PROPYLENE GLYCOL; RETINOID; SALICYLIC ACID; TAZAROTENE; UREA;

ACUTE CORONARY SYNDROME; ANAPHYLAXIS; ARTHRALGIA; BLEEDING; CHILL; CLINICAL EXAMINATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOPENIA; DAILY LIFE ACTIVITY; DEMYELINATING DISEASE; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EMOTION; EMPLOYMENT; ERYTHEMA MULTIFORME; FATIGUE; FLU LIKE SYNDROME; HEMOLYTIC ANEMIA; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; INFECTION; INJECTION SITE REACTION; LEPROSY; LISTERIOSIS; LIVER DISEASE; LIVER FAILURE; LUPUS LIKE SYNDROME; LUPUS VULGARIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MYCOBACTERIOSIS; MYCOSIS; NAIL DISEASE; NAIL INFECTION; NAUSEA; ONYCHOLYSIS; PAIN; PANCYTOPENIA; PHYSICAL EXAMINATION; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; REVIEW; SERUM SICKNESS; SIDE EFFECT; SKIN INFLAMMATION; TENOSYNOVITIS; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VASCULITIS; VIRUS INFECTION; WELLS SYNDROME;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; BIOLOGICAL THERAPY; HUMANS; IMMUNOGLOBULIN G; NAIL DISEASES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 34147106954     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2007.00112.x     Document Type: Review

References (55)

1. De Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol 2001: 144(Suppl. 58): 33-36.
2. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001: 137: 280-284.
3. De Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kekhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996: 193: 300-303.
4. Gudjonsson JE, et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients - an analysis of 1019 HLA-C and HLA-B typed patients. J Invest Dermatol 2006: 126: 740-745.
5. Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis-clinically important, potentially treatable and often overlooked. Rheumatology 2004: 43: 790-794.
6. Wynd CA, Samstag DE, Lapp AM. Bacterial carriage on the fingernails of OR nurses. AORN J 1994: 60: 799-805.
7. Toles A. Artificial nails: are they putting patients at risk? A review of the research. J Pediatr Oncol Nurs 2002: 19: 164-171.
8. Lin CM, Wu FM, Kim HK, Doyle MP, Michael BS, Williams LK. A comparision of hand washing techniques to remove Escherichia coli and calciviruses under natural or artificial fingernails. J Food Prot 2003: 66: 2296-2301.
9. Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003: 49: 206-212.
10. Baran RL. A nail psoriasis severity index. Br J Dermatol 2004: 150: 568-569.
11. Parrish CA, Sobera JO, Elewski BE. Modification of the nail psoriasis severity index. J Am Acad Dermatol 2005: 53: 745-746.
12. Lawry MA, Haneke E, Strobeck K, Martin S, Zimmer B, Romano PS. Methods for diagnosing onychomycosis: a comparative study and review of the literature. Arch Dermatol 2000: 136: 1112-1116.
13. Reisberger EM, Abels C, Landthaler M, Szeimies RM. Histopathologic diagnosis of onychomycosis by periodic acid-Schiff-stained nail clippings. Br J Dermatol 2003: 148: 749-754.
14. Weinberg JM, Koestenblatt EK, Jennings MB. Utility of histopathologic analysis in the evaluation of onychomycosis. J Am Podiatr Med Assoc 2005: 95: 258.63.
15. Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg 2004: 7: 317-321.
16. Grammer-West NY, Corvette DM, Giandoni MB, Fitzpatrick JE. Clinical pearl: nail plate biopsy for the diagnosis of psoriatic nails. J Am Acad Dermatol 1998: 38: 260-262.
17. Grover C, Reddy BSN, Chaturvedi KU. Diagnosis of nail psoriasis: importance of biopsy and histopathology. Br J Dermatol 2005: 153: 1153-1158.
18. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003: 42: 1460-1468.
19. Gladdman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005: 64(Suppl. 2): ii14-7.
20. Khan M, Schentag C, Gladman DD. Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol 2003: 30: 1022-1026.
21. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 2005: 64: 188-190.
22. Bezza A, Niamane R, Amine B, El Maghraoui A, Bensabbah R, Hajjaj-Hassouni N. Involvement of the foot in patients with psoriatic arthritis. A review of 26 cases. Joint Bone Spine 2004: 71: 546-549.
23. Fournie B, Margarit-Coll N, Champetier de Ribes TL, et al. Joint Bone Spine 2006: 73: 527-531.
24. Milosavljevic J, Lindquist U, Elvin A. Ultrasound and power Doppler evaluation of the hand and wrist in patients with psoriatic arthritis. Acta Radiol 2005: 46: 374-385.
25. Cassell S, Tutuncu Z, Lee SJ, et al. Assessment of nail involvement in psoriatic arthritis (PsA): development and validation of a modified nail psoriasis severity index (NAPSI). Arthritis Rheum 2005: 52(Suppl.): 4076.
26. Cassell S, Kavanaugh A. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006: 33: 1452-1456.
27. Nandedkar-Thomas M, Scher RK. An update on disorders of the nails. J Am Acad Dermatol 2005: 52: 877-887.
28. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biological therapy for psoriasis. Clin Therapeutics 2003: 25: 2487-2505.
29. Scheinfeld N. Alefacept: a safety profile. Expert Opin Drug Saf 2005: 4: 975-985.
30. Parrish CA, Sobera JO, Robbins CM, Cantrell WC, Desmond RA, Elewski BE. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol 2006: 5: 339-340.
31. Korver J Langewouters A Van de Kerkhof P Pasch M. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venerol 2006: 20: 1252-1255.
32. Papp KA Camisa C Stone SP, et al. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. Part II. J Cutan Med Surg 2005: 9: 313-323.
33. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006: 5: 197-209.
34. Gisondi P, Giglio MD, Girolomoni G. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study. J Dermatol Treat 2006: 17: 172-175.
35. Gaylor ML, Duvic M. Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol 2004: 3: 77-79.
36. Lowes MA, Turton JA, Krueger JG, Barnetson RS. Psoriasis vulgaris flare during efalizumab therapy does not preclude use: a case series. BMC Dermatol 2005: 18: 5-9.
37. Bang B, Gniadecki R. Severe exacerbation of psoriatic arthritis during treatment with efalizumab. A case report. Acta Derm Venereol 2006: 85: 456-457.
38. Sanchez CJL, Mahiques SL, Oliver MV. Safety of etanercept in psoriasis: a critical review. Drug Saf 2006: 29: 675-685.
39. Scheinfeld N. The medical uses and side effects of etanercept with a focus on cutaneous disease. J Drugs Dermatol 2004: 3: 653-659.
40. Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitis like reaction to subcutaneous etanercept injection. Arch Dermatol 2006: 142: 218-220.
41. Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol 2006: 142: 198-202.
42. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005: 366: 1367-1374.
43. Chavez-Lopez MA, Delgado-Villafana J, Gallaga A, Huerta-Yanez G. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol Immunopathol 2005: 33: 291-292.
44. Abedin M, Scheurich D, Reimold SC, Reimold M. Acute coronary artery syndrome after infliximab infusion. Cardiol Rev 2006: 14: 50-52.
45. Uthman I, Touma Z, El-Sayyad J, Zaitoun F. Successful retreatment with infliximab in patients with prior severe infusion reactions. Clin Rheumatol 2006: 25: 540-541.
46. Lequerre T, Vittecoq O, Klemmer N, et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 2006: 33: 1307-1314.
47. Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol 2006: 18 [Epub ahead of print].
48. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum-sickness like reactions in patients receiving intravenous infliximab. J Emerg Med 2006: 30: 41-44.
49. Wegscheider BJ, El-Shabrawi L, Weger M, et al. Adverse skin reactions to infliximab in the treatment of intraocular inflammation. Eye 2006: 3 [Epub ahead of print].
50. Scollard DM, Joyce MP, Gillis TP. Development of leprosy and type 1 reactions after treatment with infliximab: a report of two cases. Clin Infect Dis 2006: 43: e19-22.
51. Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005: 4: 637-641.
52. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007: 27: 269-274.
53. Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 2004: 50: 1690-1692.
54. Clark RA, Chong B, Mirchandani N, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006: 176: 4431-4439.
55. Kagen MH, McCormick TS, Cooer KD. Regulatory T cells in psoriasis. Ernst Schering Res Found Workshop 2006: 193-209.